Infectious Burden and Risk of Stroke: the Northern Manhattan Study
Overview
Authors
Affiliations
Objective: To determine the association between a composite measure of serological test results for common infections (Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus 1 and 2) and stroke risk in a prospective cohort study.
Design: Prospective cohort followed up longitudinally for median 8 years.
Setting: Northern Manhattan Study. Patients Randomly selected stroke-free participants from a multiethnic urban community. Main Outcome Measure Incident stroke and other vascular events.
Results: All 5 infectious serological results were available from baseline samples in 1625 participants (mean [SD] age, 68.4 [10.1] years; 64.9% women). Cox proportional hazards models were used to estimate associations of each positive serological test result with stroke. Individual parameter estimates were then combined into a weighted index of infectious burden and used to calculate hazard ratios and confidence intervals for association with risk of stroke and other outcomes, adjusted for risk factors. Each individual infection was positively, though not significantly, associated with stroke risk after adjusting for other risk factors. The infectious burden index was associated with an increased risk of all strokes (adjusted hazard ratio per standard deviation, 1.39; 95% confidence interval, 1.02-1.90) after adjusting for demographics and risk factors. Results were similar after excluding those with coronary disease (adjusted hazard ratio, 1.50; 95% confidence interval, 1.05-2.13) and adjusting for inflammatory biomarkers.
Conclusions: A quantitative weighted index of infectious burden was associated with risk of first stroke in this cohort. Future studies are needed to confirm these findings and to further define optimal measures of infectious burden as a stroke risk factor.
Cerebral microbleeds in patients with COVID-19: is there an inevitable connection?.
Wang Y, Hu Y, Zhao R, Wang Q, Xu J, Yuan J Brain Commun. 2024; 6(5):fcae236.
PMID: 39229491 PMC: 11369825. DOI: 10.1093/braincomms/fcae236.
Association between cytomegalovirus infection and dyslipidemia in US: an NHANES analysis.
Xin Y, Zhou Y Eur J Clin Microbiol Infect Dis. 2024; 43(10):1883-1897.
PMID: 39066967 DOI: 10.1007/s10096-024-04905-9.
Human Cytomegalovirus Infection and Neurocognitive and Neuropsychiatric Health.
Gale S, Farrer T, Erbstoesser R, MacLean S, Hedges D Pathogens. 2024; 13(5).
PMID: 38787269 PMC: 11123947. DOI: 10.3390/pathogens13050417.
, persistent infection burden and structural brain imaging markers.
Beydoun M, Beydoun H, Hu Y, El-Hajj Z, Georgescu M, Noren Hooten N Brain Commun. 2024; 6(2):fcae088.
PMID: 38529358 PMC: 10961948. DOI: 10.1093/braincomms/fcae088.
Interferon Upregulation Associates with Insulin Resistance in Humans.
Adeva-Andany M, Carneiro-Freire N, Castro-Quintela E, Ameneiros-Rodriguez E, Adeva-Contreras L, Fernandez-Fernandez C Curr Diabetes Rev. 2024; 21(3):86-105.
PMID: 38500280 DOI: 10.2174/0115733998294022240309105112.